Annual report pursuant to Section 13 and 15(d)

SIGNIFICANT CONCENTRATIONS (Details)

v2.4.1.9
SIGNIFICANT CONCENTRATIONS (Details) (USD $)
In Thousands, unless otherwise specified
 12 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Dec. 31, 2014
SIGNIFICANT CONCENTRATIONS      
Accounts receivable 5,750us-gaap_AccountsReceivableNetCurrent   $ 5,750us-gaap_AccountsReceivableNetCurrent
Sales [Member] | Customer Concentration Risk [Member] | Astra Zeneca A B [Member]      
SIGNIFICANT CONCENTRATIONS      
Concentration risk as a percentage of revenue 80.00%us-gaap_ConcentrationRiskPercentage1
/ us-gaap_ConcentrationRiskByBenchmarkAxis
= us-gaap_SalesMember
/ us-gaap_ConcentrationRiskByTypeAxis
= us-gaap_CustomerConcentrationRiskMember
/ us-gaap_MajorCustomersAxis
= rigl_AstraZenecaABMember 		44.00%us-gaap_ConcentrationRiskPercentage1
/ us-gaap_ConcentrationRiskByBenchmarkAxis
= us-gaap_SalesMember
/ us-gaap_ConcentrationRiskByTypeAxis
= us-gaap_CustomerConcentrationRiskMember
/ us-gaap_MajorCustomersAxis
= rigl_AstraZenecaABMember 		 
Sales [Member] | Customer Concentration Risk [Member] | Daiichi Sankyo [Member]      
SIGNIFICANT CONCENTRATIONS      
Concentration risk as a percentage of revenue 20.00%us-gaap_ConcentrationRiskPercentage1
/ us-gaap_ConcentrationRiskByBenchmarkAxis
= us-gaap_SalesMember
/ us-gaap_ConcentrationRiskByTypeAxis
= us-gaap_CustomerConcentrationRiskMember
/ us-gaap_MajorCustomersAxis
= rigl_DaiichiSankyoMember 		33.00%us-gaap_ConcentrationRiskPercentage1
/ us-gaap_ConcentrationRiskByBenchmarkAxis
= us-gaap_SalesMember
/ us-gaap_ConcentrationRiskByTypeAxis
= us-gaap_CustomerConcentrationRiskMember
/ us-gaap_MajorCustomersAxis
= rigl_DaiichiSankyoMember 		 
Sales [Member] | Customer Concentration Risk [Member] | Ber Gen Bio A S [Member]      
SIGNIFICANT CONCENTRATIONS      
Concentration risk as a percentage of revenue   22.00%us-gaap_ConcentrationRiskPercentage1
/ us-gaap_ConcentrationRiskByBenchmarkAxis
= us-gaap_SalesMember
/ us-gaap_ConcentrationRiskByTypeAxis
= us-gaap_CustomerConcentrationRiskMember
/ us-gaap_MajorCustomersAxis
= rigl_BerGenBioASMember 		 
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Astra Zeneca A B [Member]      
SIGNIFICANT CONCENTRATIONS      
Accounts receivable     5,800us-gaap_AccountsReceivableNetCurrent
/ us-gaap_ConcentrationRiskByBenchmarkAxis
= us-gaap_AccountsReceivableMember
/ us-gaap_ConcentrationRiskByTypeAxis
= us-gaap_CustomerConcentrationRiskMember
/ us-gaap_MajorCustomersAxis
= rigl_AstraZenecaABMember
Accounts Receivable [Member] | Credit Concentration Risk [Member] | Astra Zeneca A B [Member]      
SIGNIFICANT CONCENTRATIONS      
Accounts receivable 5,800us-gaap_AccountsReceivableNetCurrent
/ us-gaap_ConcentrationRiskByBenchmarkAxis
= us-gaap_AccountsReceivableMember
/ us-gaap_ConcentrationRiskByTypeAxis
= us-gaap_CreditConcentrationRiskMember
/ us-gaap_MajorCustomersAxis
= rigl_AstraZenecaABMember 		  $ 5,800us-gaap_AccountsReceivableNetCurrent
/ us-gaap_ConcentrationRiskByBenchmarkAxis
= us-gaap_AccountsReceivableMember
/ us-gaap_ConcentrationRiskByTypeAxis
= us-gaap_CreditConcentrationRiskMember
/ us-gaap_MajorCustomersAxis
= rigl_AstraZenecaABMember